Below are current clinical trials.8 studies in Stomach cancer
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to determine the long-term functional outcomes of patients undergoing total gastrectomy.
The purpose of this study is to develop and validate a brief patient reported outcomes questionaire that is responsive to ascites-related symptoms in liver cirrhosis.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
This is an open label, multi-center, Phase Ib dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX or FOLFIRI with and without bevacizumab, or regorafenib.
The purpose of this study is to determine the safety, tolerability, activity, and drug/body interactions of Oradoxel for the treatment of patients who have advanced malignancies.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of six treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.
This is a Phase I Pilot study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
The purpose of this study is to assess for the circulating nucleic acid tumor markers dispersed in the various components of blood samples from patients with proven cancer.
Aug. 29, 2017
- AskMayoExpert. Esophageal and gastric cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Niederhuber JE, et al., eds. Cancer of the stomach and gastroesophageal junction. In: Abeloff 's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. https://www.clinicalkey.com. Accessed March 23, 2016.
- Feldman M, et al. Adenocarcinoma of the stomach and other gastric tumors. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. https://www.clinicalkey.com. Accessed March 23, 2016.
- Gastric cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 23, 2016.
- Gastrointestinal stromal tumors treatment — Patient version (PDQ). National Cancer Institute. http://www.cancer.gov/types/soft-tissue-sarcoma/patient/gist-treatment-pdq. Accessed March 24, 2016.
- Palliative care. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 23, 2016.
- Singh S, et al. Physical activity is associated with reduced risk of gastric cancer: A systematic review and meta-analysis. Cancer Prevention Research. 2014;7:12.
- Carr JS, et al. Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. Journal of Gastrointestinal Cancer. 2013;44:143.
- Atasoy A, et al. Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas. https://www.uptodate.com/home. Accessed April 26, 2017.
- Goode EF, et al. Immunotherapy for gastroesophageal cancer. Journal of Clinical Medicine. 2016;5:84.
- Crane SJ, et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. American Journal of Gastroenterology. 2007;102:1596.
- Ajanai JA, et al. Esophageal and esophagogastric junction cancers, version 1.2015. Journal of the National Comprehensive Cancer Network. 2015;13:194.
- Maron SB, et al. Novel targeted therapies for esophagogastric cancer. Surgical Oncology Clinics of North America. 2017;26:293.